Novo Nordisk A/S $NVO Shares Bought by Centaurus Financial Inc.

Centaurus Financial Inc. lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 139.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,566 shares of the company’s stock after buying an additional 15,467 shares during the quarter. Centaurus Financial Inc.’s holdings in Novo Nordisk A/S were worth $1,474,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Martin Capital Partners LLC increased its position in shares of Novo Nordisk A/S by 53.8% during the third quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock worth $6,524,000 after purchasing an additional 41,129 shares in the last quarter. Smith Chas P & Associates PA Cpas lifted its holdings in shares of Novo Nordisk A/S by 105.3% in the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock valued at $22,497,000 after purchasing an additional 207,959 shares during the last quarter. Clifford Swan Investment Counsel LLC boosted its position in shares of Novo Nordisk A/S by 13.7% in the 3rd quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock valued at $17,267,000 after purchasing an additional 37,453 shares during the period. Markel Group Inc. grew its stake in Novo Nordisk A/S by 4.9% during the 3rd quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock worth $131,436,000 after buying an additional 110,061 shares during the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. acquired a new position in Novo Nordisk A/S during the third quarter worth approximately $1,294,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

NVO has been the subject of several research analyst reports. The Goldman Sachs Group reissued a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. TD Cowen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target for the company. in a research report on Tuesday, March 10th. Morgan Stanley upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target for the company in a research note on Tuesday, March 3rd. Finally, Weiss Ratings downgraded shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday. Four research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and a consensus price target of $65.56.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves higher‑dose Wegovy (Wegovy HD), showing ~20.7% mean weight loss in the STEP UP trial — approval moved through an accelerated priority pathway and Novo expects a U.S. launch in April 2026, giving the company a stronger product to regain share vs. rivals. FDA approves Novo Nordisk’s new Wegovy® HD injection
• Positive Sentiment: Sell‑side catalyst: Sanford C. Bernstein initiated coverage with an “outperform” and a high $175 PT, signaling potential upside and providing a supporting narrative for long‑term investors.
• Positive Sentiment: Real‑world retention tailwind — a study flagged that stopping GLP‑1s raises cardiovascular risks, which supports chronic use and could bolster prescription persistence for Wegovy and related products. Stopping GLP-1s raises risk of heart attack, stroke and death, study says
• Positive Sentiment: Novo is expanding access efforts in Japan (self‑pay pathways), which could add incremental revenue in a large underpenetrated market. Novo Nordisk Seeking to Expand Weight-Loss Drugs Access in Japan
• Positive Sentiment: Pipeline diversification: positive Phase‑2 data for investigational obesity candidate UBT251 (triple agonist) adds another growth option beyond semaglutide. Novo Nordisk Obesity Drug Data Sparks Questions On Valuation And Momentum
• Negative Sentiment: Patent expiration on semaglutide in India this week opens the door to low‑cost generics and potential share/pricing erosion in a large market — a clear near‑term revenue risk in that geography. Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
• Negative Sentiment: Competitive pressure intensifies — Eli Lilly confirmed superior weight‑loss with next‑gen candidate retatrutide, and Roche is re‑entering obesity, raising the risk of share loss and pricing pressure over time. Eli Lilly Confirms ‘Superior Weight Loss’ Of Its Next-Generation Obesity Drug

Novo Nordisk A/S Trading Down 1.1%

Shares of NVO stock opened at $37.05 on Friday. The company has a market capitalization of $165.44 billion, a P/E ratio of 10.68 and a beta of 0.73. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The business’s 50 day moving average is $48.67 and its two-hundred day moving average is $51.29. Novo Nordisk A/S has a twelve month low of $35.85 and a twelve month high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is currently 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.